Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

por Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., Davis, M.
Publicado 2009

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label...

por Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J.-P., Hramiak, I., Johnston, P., Davis, M.
Publicado 2009

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label...

por Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J.-P., Hramiak, I., Johnston, P., Davis, M.
Publicado 2009